Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Lactococcus rhamnosus (most commonly referred to as Lactobacillus rhamnosus GG) has been studied for its potential role in the prevention and management of eczema, particularly atopic dermatitis in children. Several randomized controlled trials and meta-analyses have investigated whether supplementation with L. rhamnosus can reduce the incidence or severity of eczema, especially when administered to pregnant women, breastfeeding mothers, or infants.

Results, however, are mixed. Some studies have found a modest reduction in eczema risk, especially when probiotics are given during pregnancy and continued after birth, while others have found no significant benefit. The quality of evidence varies, with some trials showing only short-term reduction in eczema symptoms or risk, and others finding no effect. Notably, the European Academy of Allergy and Clinical Immunology and other expert groups have concluded that there is not enough consistent evidence to recommend routine probiotic use for eczema prevention or treatment. The World Allergy Organization has issued conditional recommendations on probiotic use in high-risk infants, but specifically notes that the evidence is low quality and the effect, if present, is likely modest.

In summary, while there is scientific interest and some supportive data, the overall evidence for L. rhamnosus in supporting or treating eczema is limited and inconsistent. More high-quality, large-scale studies are needed before it can be routinely recommended for this purpose.

More about Lactococcus rhamnosus
More about Eczema

Other ingredients used for Eczema

Other health conditions supported by Lactococcus rhamnosus

Products containing Lactococcus rhamnosus